-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor On February 15, 2022, Intellia Therapeutics announced a licensing and R&D collaboration agreement with ONK Therapeutics
.
The collaboration will combine Intellia's CRISPR-based genome editing platform with ONK's optimized natural killer (NK) cell therapy platform to develop up to five CRISPR-modified allogeneic NK cell therapies
.
NK cells are naturally occurring immune cells that play a key role in immune activation against abnormal cells, including tumor cells, and thus have received much attention in the field of tumor immunotherapy
.
Intellia, co-founded by Nobel Laureate Professor Jennifer Doudna, is one of the star companies in the field of CRISPR gene editing
.
It uses a modular genome editing platform to create in vivo and in vitro therapeutic pathways covering multiple indications, with a focus on CRISPR/Cas9-based drug discovery and development of innovative cell therapies for various cancers and autoimmune diseases
.
To fully realize the translational potential of CRISPR-based technologies, Intellia is pursuing two main approaches
.
Its in vivo program uses intravenously administered CRISPR, a proprietary delivery technology that enables highly precise editing of disease-causing genes directly within specific target tissues
.
The in vitro project, based on CRISPR technology, uses engineered human cells to treat cancer and autoimmune diseases
.
▲Intellia product pipeline (Image source: Intellia's official website) ONK is committed to developing the next generation of "ready-to-use" NK cell therapy
.
With a growing preclinical pipeline targeting hematological malignancies and solid tumors, ONK is advancing multiple cell therapy candidates into the clinic
.
The company's optimized NK cell platform utilizes a suite of proprietary gene editing and cell modification strategies to optimize the cytotoxic potential, persistence and metabolic health of NK cells while reducing their depletion in the tumor microenvironment
.
Image source: ONK's official website Under the terms of the agreement, Intellia granted ONK a non-exclusive license to its ex vivo CRISPR/Cas9 genome editing technology platform and its lipid nanoparticle (LNP)-based delivery technology to develop up to 5 identical Allogeneic NK cell therapy
.
Also, ONK will acquire exclusive rights to certain Intellia guide RNAs (gRNAs) for engineering collaborative NK cell products
.
ONK will be responsible for the preclinical and clinical development of the NK cell therapy, while Intellia will be eligible to receive up to $184 million in development and commercial milestone payments, as well as potential future sales royalties
.
"We look forward to working with ONK to develop allogeneic NK cell therapy for cancer patients ," said John Leonard, Ph.
D.
, Intellia President and CEO
.
"This collaboration combines Intellia's CRISPR technology platform with ONK's NK cell technology.
Our expertise provides yet another powerful example of how we leverage strategic collaborations to address life-threatening diseases
.
"We believe that combining Intellia's ex vivo genome editing and LNP delivery platform with our suite of proprietary NK cell gene editing [technologies] has the potential to create cytotoxicity-enhancing, Optimally engineered NK cells with persistence and improved metabolic profile hold great promise for advancing the treatment of hematological malignancies and solid tumors
.
"Reference: [1] Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer.
Retrieved February 15, 2022, from https://ir.
intelliatx.
com/news-releases /news-release-details/intellia-and-onk-therapeutics-announce-collaboration-advance Disclaimer: WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the opinions in this article do not represent medicines The position of WuXi AppTec does not mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
.
The collaboration will combine Intellia's CRISPR-based genome editing platform with ONK's optimized natural killer (NK) cell therapy platform to develop up to five CRISPR-modified allogeneic NK cell therapies
.
NK cells are naturally occurring immune cells that play a key role in immune activation against abnormal cells, including tumor cells, and thus have received much attention in the field of tumor immunotherapy
.
Intellia, co-founded by Nobel Laureate Professor Jennifer Doudna, is one of the star companies in the field of CRISPR gene editing
.
It uses a modular genome editing platform to create in vivo and in vitro therapeutic pathways covering multiple indications, with a focus on CRISPR/Cas9-based drug discovery and development of innovative cell therapies for various cancers and autoimmune diseases
.
To fully realize the translational potential of CRISPR-based technologies, Intellia is pursuing two main approaches
.
Its in vivo program uses intravenously administered CRISPR, a proprietary delivery technology that enables highly precise editing of disease-causing genes directly within specific target tissues
.
The in vitro project, based on CRISPR technology, uses engineered human cells to treat cancer and autoimmune diseases
.
▲Intellia product pipeline (Image source: Intellia's official website) ONK is committed to developing the next generation of "ready-to-use" NK cell therapy
.
With a growing preclinical pipeline targeting hematological malignancies and solid tumors, ONK is advancing multiple cell therapy candidates into the clinic
.
The company's optimized NK cell platform utilizes a suite of proprietary gene editing and cell modification strategies to optimize the cytotoxic potential, persistence and metabolic health of NK cells while reducing their depletion in the tumor microenvironment
.
Image source: ONK's official website Under the terms of the agreement, Intellia granted ONK a non-exclusive license to its ex vivo CRISPR/Cas9 genome editing technology platform and its lipid nanoparticle (LNP)-based delivery technology to develop up to 5 identical Allogeneic NK cell therapy
.
Also, ONK will acquire exclusive rights to certain Intellia guide RNAs (gRNAs) for engineering collaborative NK cell products
.
ONK will be responsible for the preclinical and clinical development of the NK cell therapy, while Intellia will be eligible to receive up to $184 million in development and commercial milestone payments, as well as potential future sales royalties
.
"We look forward to working with ONK to develop allogeneic NK cell therapy for cancer patients ," said John Leonard, Ph.
D.
, Intellia President and CEO
.
"This collaboration combines Intellia's CRISPR technology platform with ONK's NK cell technology.
Our expertise provides yet another powerful example of how we leverage strategic collaborations to address life-threatening diseases
.
"We believe that combining Intellia's ex vivo genome editing and LNP delivery platform with our suite of proprietary NK cell gene editing [technologies] has the potential to create cytotoxicity-enhancing, Optimally engineered NK cells with persistence and improved metabolic profile hold great promise for advancing the treatment of hematological malignancies and solid tumors
.
"Reference: [1] Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer.
Retrieved February 15, 2022, from https://ir.
intelliatx.
com/news-releases /news-release-details/intellia-and-onk-therapeutics-announce-collaboration-advance Disclaimer: WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the opinions in this article do not represent medicines The position of WuXi AppTec does not mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
